Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RTOG 0241 A PHASE I STUDY OF IRINOTECAN AND CISPLATIN IN COMBINATION WITH TWICE DAILY THORACIC RADIOTHERAPY (45 GyOR ONCE DAILY THORACIC RADIOTHERAPY(70 Gy) FOR PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER).

Next Previous
Trial Profile

RTOG 0241 A PHASE I STUDY OF IRINOTECAN AND CISPLATIN IN COMBINATION WITH TWICE DAILY THORACIC RADIOTHERAPY (45 GyOR ONCE DAILY THORACIC RADIOTHERAPY(70 Gy) FOR PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER).

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Cisplatin
  • Indications Small cell lung cancer
  • Focus Adverse reactions

Most Recent Events

  • 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
  • 30 Jun 2009 Additional lead trial investigator Hageboutros A identified as reported by New Jersey Cancer Trial Connect.
  • 04 Nov 2008 Checked against ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top